180 Life Sciences Corp. has announced that it is facing delisting from The Nasdaq Stock Market due to non-compliance with the minimum stockholders' equity requirement. The company was initially notified by Nasdaq on November 15, 2023, and was given until May 13, 2024, to regain compliance. Failing to meet the requirement, the company received a delisting determination letter on May 14, 2024, with a suspension of trading set to commence on May 23, 2024. However, 180 Life Sciences has appealed the decision, and the delisting action has been stayed pending a final decision by the Nasdaq Hearings Panel. The company plans to present a compliance plan at the Panel hearing. In the meantime, trading of the company's common stock and public warrants will continue on Nasdaq under the...Show More

180 Life Sciences Corp. has announced that it is facing delisting from The Nasdaq Stock Market due to non-compliance with the minimum stockholders' equity requirement. The company was initially notified by Nasdaq on November 15, 2023, and was given until May 13, 2024, to regain compliance. Failing to meet the requirement, the company received a delisting determination letter on May 14, 2024, with a suspension of trading set to commence on May 23, 2024. However, 180 Life Sciences has appealed the decision, and the delisting action has been stayed pending a final decision by the Nasdaq Hearings Panel. The company plans to present a compliance plan at the Panel hearing. In the meantime, trading of the company's common stock and public warrants will continue on Nasdaq under the symbols 'ATNF' and 'ATNFW'. The company acknowledges that there is no assurance that its plan will be accepted or that it will be able to regain compliance with Nasdaq's listing requirements. The potential delisting could negatively impact the company's stock and warrant prices, its ability to raise capital, and could trigger defaults and penalties under existing agreements.